Magnesium chloride

Identification

Name
Magnesium chloride
Accession Number
DB09407
Type
Small Molecule
Groups
Approved
Description

Magnesium chloride salts are typical ionic halides, being highly soluble in water. The hydrated magnesium chloride can be extracted from brine or sea water.

Structure
Thumb
Synonyms
  • Anhydrous magnesium chloride
  • Magnesium chloride anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Magnesium chloride hexahydrate02F3473H9O7791-18-6DHRRIBDTHFBPNG-UHFFFAOYSA-L
Magnesium chloride hydrateNot Available22756-14-5MJMDTFNVECGTEM-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Magnesium cationionicT6V3LHY83822537-22-0JLVVSXFLKOJNIY-UHFFFAOYSA-N
Chloride ionionicQ32ZN4869816887-00-6VEXZGXHMUGYJMC-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cepasium Sup 100mgSuppository100 mgRectalLaboratoires Cortunon Inc.1980-12-311998-09-29Canada
Magnesium-35 0.5 - 4.5Powder, for solution16 gHemodialysisBaxter Laboratories1990-12-312002-08-01Canada
Magnesium-35 0.25 - 4.5Powder, for solution8 gHemodialysisAlthin Biopharm Inc.1988-12-311999-09-23Canada
Magnesium-36.8 0.25-4.5Powder8.4 gHemodialysisAlthin Biopharm Inc.1995-12-311999-09-23Canada
Magnesium-36.8 0.5-4.5Powder16.8 gHemodialysisBaxter Laboratories1995-12-312002-08-01Canada
Magnesium-45 0.5-4.5Powder, for solution20.5 gHemodialysisBaxter Laboratories1996-12-31Not applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Formule 454Liquid200 mgOralLe Naturiste J.M.B. Inc.1980-12-312002-01-10Canada
Magnesium Chloride 606.5mgTablet606.5 mgOralBio Vita1987-12-312006-07-27Canada
Magnesium Liq 2.87mg/mlLiquid24 mgOralVitalab1990-12-312005-07-12Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
2.5% Travasol Amino Acid Injection With Electrolytes In 10% DextroseMagnesium chloride (25.5 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + L-Alanine (520 mg) + L-Arginine (290 mg) + L-Isoleucine (150 mg) + L-Leucine (182.5 mg) + L-Lysine (145 mg) + L-Phenylalanine (140 mg) + L-Proline (170 mg) + L-Threonine (105 mg) + L-Tryptophan (45 mg) + L-Tyrosine (10 mg) + L-Valine (145 mg) + Methionine (100 mg) + Serine (125 mg) + Sodium Chloride (29.3 mg) + Sodium acetate (170 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312015-08-05Canada
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose ClinimixMagnesium chloride (25.5 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (520 mg) + Histidine (110 mg) + L-Alanine (520 mg) + L-Arginine (260 mg) + L-Isoleucine (120 mg) + L-Leucine hydrochloride (155 mg) + L-Lysine hydrochloride (145 mg) + Phenylalanine hydrochloride (155 mg) + L-Proline (105 mg) + L-Threonine (105 mg) + L-Tryptophan (45 mg) + L-Tyrosine (10 mg) + L-Valine (115 mg) + Methionine (145 mg) + Sodium Chloride (29.3 mg) + Sodium acetate (170 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312015-08-05Canada
2.5%travasol Amino Acid InJ.W.eleC.W.25%dexMagnesium chloride (25.5 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + L-Alanine (520 mg) + L-Arginine (290 mg) + L-Isoleucine (150 mg) + L-Leucine (182.5 mg) + L-Lysine (145 mg) + L-Phenylalanine (140 mg) + L-Proline (170 mg) + L-Threonine (105 mg) + L-Tryptophan (45 mg) + L-Tyrosine (10 mg) + L-Valine (145 mg) + Methionine (100 mg) + Serine (125 mg) + Sodium Chloride (29.3 mg) + Sodium acetate (170 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travas. Amino Acid InJ.W.elecw.25%dexMagnesium chloride (51 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + L-Alanine (570 mg) + L-Arginine (316 mg) + L-Isoleucine (165 mg) + L-Leucine (201 mg) + L-Lysine (159.5 mg) + L-Phenylalanine (154 mg) + L-Proline (187 mg) + L-Threonine (115.5 mg) + L-Tryptophan (49.5 mg) + L-Tyrosine (11 mg) + L-Valine (159.5 mg) + Methionine (110 mg) + Serine (137.5 mg) + Sodium Chloride (112 mg) + Sodium acetate (215.5 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose QuickmixMagnesium chloride (51 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (570 mg) + Histidine (120.5 mg) + L-Alanine (570 mg) + L-Arginine (285 mg) + L-Isoleucine (131.5 mg) + L-Leucine hydrochloride (170 mg) + L-Lysine hydrochloride (159 mg) + Phenylalanine hydrochloride (170 mg) + L-Proline (115 mg) + L-Threonine (115 mg) + L-Tryptophan (49.5 mg) + L-Tyrosine (11 mg) + L-Valine (126 mg) + Methionine (159 mg) + Sodium Chloride (112 mg) + Sodium acetate (215.5 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-02-022007-08-02Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 5% Dextrose QuickmixMagnesium chloride (51 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (215.5 mg) + Glycine (570 mg) + Histidine (120.5 mg) + L-Alanine (570 mg) + L-Arginine (285 mg) + L-Isoleucine (131.5 mg) + L-Leucine hydrochloride (170 mg) + L-Lysine hydrochloride (159 mg) + Phenylalanine hydrochloride (170 mg) + L-Proline (115 mg) + L-Threonine (115 mg) + L-Tryptophan (49.5 mg) + L-Tyrosine (11 mg) + L-Valine (126 mg) + Methionine (159 mg) + Sodium Chloride (112 mg) + Sodium acetate (256 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312007-08-02Canada
2.75%travasol Amino Acid InJ.W.eleC.W.5%dex.Magnesium chloride (51 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + L-Alanine (570 mg) + L-Arginine (316 mg) + L-Isoleucine (165 mg) + L-Leucine (201 mg) + L-Lysine (159.5 mg) + L-Phenylalanine (154 mg) + L-Proline (187 mg) + L-Threonine (115.5 mg) + L-Tryptophan (49.5 mg) + L-Tyrosine (11 mg) + L-Valine (159.5 mg) + Methionine (110 mg) + Serine (137.5 mg) + Sodium Chloride (112 mg) + Sodium acetate (215 mg)LiquidIntravenousClintec Nutrition Company1996-12-311999-08-10Canada
4.25% Travasol Amino Acid Injection With Electrolytes In 10% DextroseMagnesium chloride (51 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (261 mg) + Glycine (438 mg) + Histidine (204 mg) + L-Alanine (880 mg) + L-Arginine (489 mg) + L-Isoleucine (255 mg) + L-Leucine (310 mg) + L-Lysine hydrochloride (246.5 mg) + L-Phenylalanine (238 mg) + L-Proline (289 mg) + L-Threonine (178.5 mg) + L-Tryptophan (76.5 mg) + L-Tyrosine (17 mg) + L-Valine (246.5 mg) + Methionine (170 mg) + Serine (212.5 mg) + Sodium Chloride (77 mg) + Sodium acetate (297 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312015-08-05Canada
4.25% Travasol Amino Acid Injection With Electrolytes In 20% DextroseMagnesium chloride (51 mg) + Dextrose, unspecified form (20 g) + Dipotassium phosphate (261 mg) + Glycine (438 mg) + Histidine (204 mg) + L-Alanine (880 mg) + L-Arginine (489 mg) + L-Isoleucine (255 mg) + L-Leucine (310 mg) + L-Lysine hydrochloride (246.5 mg) + L-Phenylalanine (238 mg) + L-Proline (289 mg) + L-Threonine (178.5 mg) + L-Tryptophan (76.5 mg) + L-Tyrosine (17 mg) + L-Valine (246.5 mg) + Methionine (170 mg) + Serine (212.5 mg) + Sodium Chloride (77 mg) + Sodium acetate (297 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312007-08-02Canada
4.25% Travasol Amino Acid Injection With Electrolytes In 20% Dextrose QuickmixMagnesium chloride (51 mg) + Dextrose, unspecified form (20 g) + Dipotassium phosphate (261 mg) + Glycine (880 mg) + Histidine (186 mg) + L-Alanine (880 mg) + L-Arginine (440 mg) + L-Isoleucine (203 mg) + L-Leucine hydrochloride (263 mg) + L-Lysine hydrochloride (246 mg) + Phenylalanine hydrochloride (263 mg) + L-Proline (178 mg) + L-Threonine (178 mg) + L-Tryptophan (76 mg) + L-Tyrosine (17 mg) + L-Valine (195 mg) + Methionine (246 mg) + Sodium Chloride (77 mg) + Sodium acetate (297 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312007-08-02Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ChloromagMagnesium chloride hexahydrate (200 mg/1mL)Injection, solutionIntravenousMerit Pharmaceuticals2011-06-11Not applicableUs
Cytosol Ophthalmics - Balanced Salt SolutionMagnesium chloride hexahydrate (30 mg/1mL) + Calcium chloride dihydrate (48 mg/1mL) + Potassium Chloride (75 mg/1mL) + Sodium Chloride (6.40 mg/1mL) + Sodium citrate dihydrate (1.70 mg/1mL) + Sodium acetate trihydrate (3.90 mg/1mL)SolutionIrrigationBiomet Biologics2010-01-012010-09-04Us
Hyperlyte CRMagnesium chloride hexahydrate (0.51 g/20mL) + Calcium chloride dihydrate (0.37 g/20mL) + Potassium acetate (1.96 g/20mL) + Sodium Chloride (1.17 g/20mL) + Sodium acetate trihydrate (0.68 g/20mL)Injection, solution, concentrateIntravenousB. Braun Medical Inc.2012-04-12Not applicableUs
Magnesium ChlorideMagnesium chloride hexahydrate (200 mg/1mL)Injection, solutionIntravenousAmerican Therapeutic Medicines Inc.2009-05-012010-12-30Us
Magnesium ChlorideMagnesium chloride hexahydrate (200 mg/1mL)InjectionIntravenousMylan Teoranta2013-03-142015-01-15Us
Magnesium ChlorideMagnesium chloride hexahydrate (200 mg/1mL)InjectionIntravenousMylan Institutional LLC2013-03-14Not applicableUs
Magnesium ChlorideMagnesium chloride hexahydrate (200 mg/1mL)Injection, solutionIntravenousAmerican Regent1990-09-302014-08-01Us
Magnesium ChlorideMagnesium chloride hexahydrate (200 mg/1mL)Injection, solutionIntravenousClaris Lifesciences Limited2009-10-072010-11-04Us
Magnesium ChlorideMagnesium chloride hexahydrate (200 mg/1mL)Injection, solutionIntravenousThe Torrance Company1990-09-032016-11-18Us
Nutrilyte IIMagnesium chloride hexahydrate (25.5 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Potassium acetate (98 mg/1mL) + Sodium Chloride (74.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012014-01-01Us
Categories
UNII
59XN63C8VM
CAS number
7786-30-3
Weight
Average: 95.211
Monoisotopic: 93.922747312
Chemical Formula
Cl2Mg
InChI Key
TWRXJAOTZQYOKJ-UHFFFAOYSA-L
InChI
InChI=1S/2ClH.Mg/h2*1H;/q;;+2/p-2
IUPAC Name
magnesium(2+) ion dichloride
SMILES
[Mg++].[Cl-].[Cl-]

Pharmacology

Indication

Magnesium chloride is used in several medical and topical (skin related) applications. Magnesium chloride usp, anhydrous uses as electrolyte replenisher, pharmaceutic necessity for hemodialysis and peritoneal dialysis fluids.

Associated Conditions
Associated Therapies
Pharmacodynamics

Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).

Mechanism of action

Mechanism of action of magnesium chloride studied in 10 adult volunteers. Results suggested magnesium ion in duodenum is relatively weak stimulus to pancreas and gall bladder. It is weak stimulant to cholecystokinin release and inhibits net jejunal water absorption. The oral administration of a single 800 mg dose of magnesium chloride in healthy volunteers resulted in a diminished rate of intraluminal lipid and protein digestion. The most pronounced effect of magnesium chloride, however, was a decreased gastric emptying rate of both test meals. After correction for gastric emptying, no differences were noted in intraluminal lipid or protein digestion. Therefore, the lower lipid levels noted after magnesium supplementation are unlikely to be the result of altered lipid assimilation. Magnesium chloride slows gastric emptying but does not influence lipid digestion.

Absorption

Oral: Inversely proportional to amount ingested; 40% to 60% under controlled dietary conditions; 15% to 36% at higher doses

Volume of distribution

Bone (50% to 60%); extracellular fluid (1% to 2%)

Protein binding

30%, to albumin

Metabolism

Magnesium levels are efficiently regulated by the kidneys. Magnesium also undergoes efficient enterohepatic circulation

Route of elimination

Magnesium is excreted in urine. Unabsorbed magnesium is excreted in feces

Half life

Elimination half-life has been reported to be 27.7 hours following an overdose of 400 mEq magnesium in an adult.

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance.

Toxicity

Mouse LD50 775mg/kg (intraperitoneal) Mouse LD50 : 7600mg/kg (oral) Rat LD 50 : 8100mg/kg (oral) Rat LD50 176mg/kg (intravenous) Severe toxicity occurs most often after intravenous infusions. It can also occur after chronic excessive oral doses, often in patients with renal insufficiency. Early manifestations are lethargy, hyporeflexia, followed by weakness, paralysis, hypotension, ECG changes (prolonged PR and QRS intervals), CNS depression, seizures, and respiratory depression. In overdose, magnesium impairs neuromuscular transmission, manifested as weakness and hyporeflexia.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1alpha-Hydroxyvitamin D5The serum concentration of Magnesium chloride can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Magnesium chloride is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-Aza-2,3-Dihydrogeranyl DiphosphateMagnesium chloride can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Magnesium chloride.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Magnesium chloride.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Magnesium chloride.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Magnesium chloride is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Magnesium chloride.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Magnesium chloride.
AbacavirAbacavir may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. DRUGS.COM [Link]
  3. Pubchem [Link]
  4. Toxnet [Link]
  5. ChemIDplus [Link]
External Links
KEGG Compound
C07755
PubChem Compound
5360315
PubChem Substance
347827844
ChemSpider
22987
ChEBI
6636
ChEMBL
CHEMBL2219642
Wikipedia
Magnesium_chloride
ATC Codes
A12CC01 — Magnesium chlorideB05XA11 — Magnesium chloride
AHFS Codes
  • 40:34.00* — Hemodialysis Solution
  • 88:29.00* — Minerals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHealthy Volunteers1
1, 2CompletedOtherGlaucoma1
1, 2Not Yet RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS)1
2Active Not RecruitingTreatmentCardiopulmonary Bypass / Surgery, Cardiac1
2CompletedPreventionAcute Kidney Injury (AKI)1
2CompletedTreatmentCataracts1
2CompletedTreatmentNeoplasms, Brain1
2CompletedTreatmentRespiratory Distress Syndrome, Adult1
2CompletedTreatmentSymptomatic Focal Vitreomacular Adhesion1
2CompletedTreatmentΒ-Thalassemia Intermedia1
2RecruitingTreatmentAnterior Wall Myocardial Infarction1
2TerminatedTreatmentCongestive Heart Failure (CHF)1
2, 3Active Not RecruitingTreatmentDepression1
2, 3CompletedTreatmentGlaucoma1
2, 3CompletedTreatmentStrokes1
3CompletedTreatmentCataracts2
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
3CompletedTreatmentContinuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / End Stage Renal Disease (ESRD)1
3CompletedTreatmentDiabetes Mellitus (DM) / ESRD1
3Enrolling by InvitationTreatmentAnaesthesia therapy1
3RecruitingTreatmentAcidosis, Metabolic / Critical Illness1
3Unknown StatusTreatmentCongestive Heart Failure (CHF)1
4CompletedPreventionInflammatory Reaction1
4CompletedTreatmentAPD / Continuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / ESRD1
4CompletedTreatmentGlaucoma / Intraocular Pressure1
4RecruitingTreatmentHypovolaemia1
4RecruitingTreatmentImpaired Renal Function1
4WithdrawnTreatmentClostridium Difficile Infection (CDI)1
Not AvailableCompletedTreatmentCataracts1
Not AvailableRecruitingTreatmentEnd Stage Renal Disease (ESRD)1
Not AvailableRecruitingTreatmentShock / Shock, Septic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, for solutionIntraocular
SolutionIntraocular
SolutionIrrigation
LiquidHemodialysis
Kit
Kit; solutionIntraocular
SolutionIntra-arterial
SuppositoryRectal100 mg
Injection, solutionIntraperitoneal
SolutionIntrathecal
SolutionIntraperitoneal
SolutionOphthalmic
LiquidOral200 mg
Injection, solution, concentrateIntravenous
LiquidIntraperitoneal
SolutionHemodialysis; Intraperitoneal
LiquidIntraocular
InjectionIntravenous200 mg/1mL
Injection, solutionIntravenous200 mg/1mL
TabletOral606.5 mg
LiquidOral24 mg
Powder, for solutionHemodialysis16 g
Powder, for solutionHemodialysis8 g
PowderHemodialysis8.4 g
PowderHemodialysis16.8 g
Powder, for solutionHemodialysis20.5 g
TabletOral
LiquidBuccal
SprayBuccal
LiquidIntravenous
SolutionHemodialysis
Kit; solutionIntraocular; Irrigation
EmulsionIntravenous
IrrigantIrrigation
Injection, solutionIntravenous
SolutionIntravenous
Injection, solutionIntra-arterial
Solution
SolutionHemodialysis; Intravenous
AerosolOral
InjectionIntravenous
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5945449No1997-10-312017-10-31Us
US7300674No2003-03-042023-03-04Us
US6077836No1997-06-202017-06-20Us
US6248726No1998-06-192018-06-19Us
US7084130No2001-11-292021-11-29Us

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.61ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity5.62 m3·mol-1ChemAxon
Polarizability2.39 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a lanthanide.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal salts
Sub Class
Alkaline earth metal chlorides
Direct Parent
Alkaline earth metal chlorides
Alternative Parents
Inorganic chloride salts
Substituents
Alkaline earth metal chloride / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
inorganic chloride, magnesium salt, magnesium halide (CHEBI:6636)

Drug created on November 30, 2015 12:10 / Updated on November 14, 2018 13:02